Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Phase I Trial
100%
High-dose Chemotherapy
100%
Carboplatin
100%
Area under the Concentration-time Curve
100%
Peripheral Blood Stem Cells
100%
Autologous Peripheral Blood Stem Cells
100%
Granulocyte Colony-stimulating Factor (G-CSF)
80%
High Dose
60%
Paclitaxel
60%
Cyclophosphamide
40%
Stem Cell Support
40%
Median Time
20%
Clinical Trials
20%
Clinical Outcomes
20%
Reperfusion
20%
Time to Progression
20%
Etoposide
20%
Diarrhea
20%
Dehydration
20%
Dose-limiting Toxicity
20%
Maximum Tolerated Dose
20%
Complete Clinical Response
20%
Conventional Dose
20%
Overall Response Rate
20%
Prior Chemotherapy
20%
Electrolyte Imbalance
20%
Frontline Therapy
20%
One-cycle
20%
Toxicity Outcomes
20%
Malignant Solid Tumor
20%
Clinical Response Rate
20%
Medicine and Dentistry
Phase I Trials
100%
High Dose Chemotherapy
100%
Peripheral Blood Stem Cell
100%
Carboplatin
83%
Granulocyte Macrophage Colony Stimulating Factor
66%
Drug Megadose
50%
Paclitaxel
50%
Cyclophosphamide
33%
Solid Malignant Neoplasm
16%
Clinical Trial
16%
Etoposide
16%
Diarrhea
16%
Patient History of Chemotherapy
16%
Disorders of Calcium Metabolism
16%
Pharmacology, Toxicology and Pharmaceutical Science
Phase I Trials
100%
High Dose Chemotherapy
100%
Carboplatin
100%
Granulocyte Macrophage Colony Stimulating Factor
80%
Paclitaxel
60%
Cyclophosphamide
40%
Clinical Trial
20%
Etoposide
20%
Maximum Tolerated Dose
20%
Solid Malignant Neoplasm
20%
Diarrhea
20%
Patient History of Chemotherapy
20%
Electrolyte Disturbance
20%